New hope for tough pancreatic cancer: testing dual drug attack
NCT ID NCT06313970
Summary
This study is testing whether adding a new immunotherapy drug (QL1706) to standard chemotherapy works better for people with advanced pancreatic cancer that cannot be removed by surgery. It will involve 58 adults who have not yet received any treatment for their advanced cancer. Researchers want to see if the new combination helps shrink tumors and is safe, comparing it to the same combination plus another targeted drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.